Open Access

Multicenter study of zoledronic acid administration in non‑small‑cell lung cancer patients with bone metastasis: Thoracic Oncology Research Group (TORG) 1017

  • Authors:
    • Yoshiro Nakahara
    • Yukio Hosomi
    • Masahiko Shibuya
    • Hisashi Mitsufuji
    • Masato Katagiri
    • Katsuhiko Naoki
    • Kenzo Soejima
    • Naoyuki Nogami
    • Seisuke Nagase
    • Masanori Nishikawa
    • Koichi Minato
    • Yuichi Takiguchi
    • Nobuhiko Seki
    • Kouzo Yamada
    • Takashi Seto
    • Hiroaki Okamoto
  • View Affiliations

  • Published online on: July 23, 2019     https://doi.org/10.3892/mco.2019.1903
  • Pages: 349-353
  • Copyright: © Nakahara et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Skeletal‑related events (SREs) may occur at the time of first diagnosis in 20‑30% of lung cancer patients with bone metastases. Several clinical trials have shown that zoledronic acid (ZA) is effective for decreasing SREs. The main objective of the present study was to discuss clinical data of ZA and compare the frequency of SREs with previous reports. All patients with non‑small‑cell lung cancer (NSCLC) with metastatic bone disease who were administered ZA at least twice between January 2008 and December 2009 were eligible for inclusion in the study. In total, 198 consecutive patients were identified. The median duration of ZA administration was 106 days [95% confidence interval (CI), 92‑133 days], and the median number of ZA administrations was 4 (range, 2‑41). The median time to first SRE in patients who experienced SRE following ZA treatment was 202 days (95% CI, 156‑264 days). Among the 78 patients who had already experienced SRE prior to ZA treatment, 35 (45%) experienced SRE subsequently after starting ZA treatment. On the other hand, among the 120 patients without a history of SRE before starting ZA treatment, 42 (35%) experienced SRE after the start of ZA administration (P=0.16). No osteonecrosis of the jaw (ONJ) was reported in any of the patients. The present study revealed that ZA had a certain level of efficacy regardless of the presence or absence of prior SREs. However, the duration of ZA therapy was short in this study; further accumulation of data on the long‑term prognosis and incidence rates of ONJ and other late complications of ZA therapy seems to be particularly important.

References

1 

Katakami N, Kunikane H, Takeda K, Takayama K, Sawa T, Saito H, Harada M, Yokota S, Ando K, Saito Y, et al: Prospective study on the incidence of bone metastasis (BM) and skeletal-related events (SREs) in patients (pts) with stage IIIB and IV lung cancer-CSP-HOR 13. J Thorac Oncol. 9:231–238. 2014. View Article : Google Scholar : PubMed/NCBI

2 

Tsuya A, Kurata T, Tamura K and Fukuoka M: Skeletal metastases in non-small cell lung cancer: A retrospective study. Lung Cancer. 57:229–232. 2007. View Article : Google Scholar : PubMed/NCBI

3 

Oster G, Lamerato L, Glass AG, Richert-Boe KE, Lopez A, Chung K, Richhariya A, Dodge T, Wolff GG, Balakumaran A and Edelsberg J: Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: A 15-year study in two large US health systems. Support Care Cancer. 21:3279–3286. 2013. View Article : Google Scholar : PubMed/NCBI

4 

Yoneda T and Hiraga T: Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem Biophys Res Commun. 328:679–687. 2005. View Article : Google Scholar : PubMed/NCBI

5 

Saylor PJ and Smith MR: Bisphosphonates and other bone-targeted therapies. Cancer Chemotherapy and Biotherapy: Principles and Practice. 5th. Chabner BA and Longo DL: Wolters Kluwer Lippincott Williams & Wilkins; Philadelphia: pp. 732–745. 2011

6 

Roelofs AJ, Thompson K, Gordon S and Rogers MJ: Molecular mechanisms of action of bisphosphonates: Current status. Clin Cancer Res. 12:6222s–6230s. 2006. View Article : Google Scholar : PubMed/NCBI

7 

Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, de Souza P, Zheng M, Urbanowitz G, et al: Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial-the Zoledronic acid lung cancer and other solid tumors study group. J Clin Oncol. 21:3150–3157. 2003. View Article : Google Scholar : PubMed/NCBI

8 

Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, De Souza P, Zheng M, Urbanowitz G, et al: Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: A randomized, Phase III, double-blind, placebo-controlled trial. Cancer. 100:2613–2621. 2004. View Article : Google Scholar : PubMed/NCBI

9 

Hirsh V, Major PP, Lipton A, Cook RJ, Langer CJ, Smith MR, Brown JE and Coleman RE: Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol. 3:228–236. 2008. View Article : Google Scholar : PubMed/NCBI

10 

Hirsh V, Tchekmedyian NS, Rosen LS, Zheng M and Hei YJ: Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: Analysis based on history of skeletal complications. Clin Lung Cancer. 6:170–174. 2004. View Article : Google Scholar : PubMed/NCBI

11 

Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, et al: Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol. 23:8580–8587. 2005. View Article : Google Scholar : PubMed/NCBI

12 

Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, et al Bisphosphonate-associated osteonecrosis of the jaw, : Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 22:1479–1491. 2007. View Article : Google Scholar : PubMed/NCBI

13 

Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis CG, Boukovinas I, Koloutsos GE, Teleioudis Z, Kitikidou K, et al: Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol. 27:5356–5362. 2009. View Article : Google Scholar : PubMed/NCBI

14 

Van Poznak CH, Temin S, Yee GC, Janjan NA, Barlow WE, Biermann JS, Bosserman LD, Geoghegan C, Hillner BE, Theriault RL, et al: American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol. 29:1221–1227. 2011. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

October 2019
Volume 11 Issue 4

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Nakahara, Y., Hosomi, Y., Shibuya, M., Mitsufuji, H., Katagiri, M., Naoki, K. ... Okamoto, H. (2019). Multicenter study of zoledronic acid administration in non‑small‑cell lung cancer patients with bone metastasis: Thoracic Oncology Research Group (TORG) 1017. Molecular and Clinical Oncology, 11, 349-353. https://doi.org/10.3892/mco.2019.1903
MLA
Nakahara, Y., Hosomi, Y., Shibuya, M., Mitsufuji, H., Katagiri, M., Naoki, K., Soejima, K., Nogami, N., Nagase, S., Nishikawa, M., Minato, K., Takiguchi, Y., Seki, N., Yamada, K., Seto, T., Okamoto, H."Multicenter study of zoledronic acid administration in non‑small‑cell lung cancer patients with bone metastasis: Thoracic Oncology Research Group (TORG) 1017". Molecular and Clinical Oncology 11.4 (2019): 349-353.
Chicago
Nakahara, Y., Hosomi, Y., Shibuya, M., Mitsufuji, H., Katagiri, M., Naoki, K., Soejima, K., Nogami, N., Nagase, S., Nishikawa, M., Minato, K., Takiguchi, Y., Seki, N., Yamada, K., Seto, T., Okamoto, H."Multicenter study of zoledronic acid administration in non‑small‑cell lung cancer patients with bone metastasis: Thoracic Oncology Research Group (TORG) 1017". Molecular and Clinical Oncology 11, no. 4 (2019): 349-353. https://doi.org/10.3892/mco.2019.1903